Enterprise Value
120.8M
Cash
38.76M
Avg Qtr Burn
-11.39M
Short % of Float
7.20%
Insider Ownership
9.56%
Institutional Own.
46.38%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Avasopasem Manganese (GC4419) Details Head and neck cancer, Cancer | NDA Resubmission | |
Avasopasem Manganese (GC4419) Details Lung cancer, Esophagitis, Non-small cell lung carcinoma | Phase 2a Update | |
Avasopasem Manganese (GC4419) Details Infectious disease, COVID-19 | Failed Discontinued | |
Rucosopasem Details Cancer, Non-small cell lung carcinoma | Failed Discontinued | |
Rucosopasem Details Pancreatic cancer, Cancer | Failed Discontinued |